What was studied?
An open-label randomized trial compared tesamorelin with standard care for six months in people with HIV and abdominal obesity.
What did the researchers report?
Waist circumference decreased more in the tesamorelin group, but neurocognitive change did not differ significantly between groups.
What are the limits?
A within-group trend is not a positive randomized comparison. The small study lacked a placebo arm and does not establish cognitive enhancement from reducing abdominal fat.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.